Arrowhead ResearchARWR
ARWR
About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Employees: 525
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 88
0% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 34
1% less funds holding
Funds holding: 271 [Q2] → 268 (-3) [Q3]
3.25% less ownership
Funds ownership: 82.08% [Q2] → 78.83% (-3.25%) [Q3]
28% less capital invested
Capital invested by funds: $2.65B [Q2] → $1.9B (-$754M) [Q3]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]
61% less call options, than puts
Call options by funds: $3.3M | Put options by funds: $8.52M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
22%
upside
Avg. target
$47
139%
upside
High target
$80
307%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 40% 1-year accuracy 70 / 175 met price target | 307%upside $80 | Buy Reiterated | 23 Jan 2025 |
Chardan Capital Keay Nakae 26% 1-year accuracy 19 / 74 met price target | 205%upside $60 | Buy Maintained | 12 Dec 2024 |
Bernstein William Pickering 29% 1-year accuracy 2 / 7 met price target | 22%upside $24 | Market Perform Maintained | 29 Nov 2024 |
Piper Sandler Edward Tenthoff 28% 1-year accuracy 12 / 43 met price target | 129%upside $45 | Overweight Maintained | 27 Nov 2024 |
Citigroup Shawn Egan 0 / 0 met price target | 32%upside $26 | Neutral Maintained | 27 Nov 2024 |
Financial journalist opinion
Based on 3 articles about ARWR published over the past 30 days
Neutral
PRNewsWire
1 week ago
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600
NEW YORK , Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE: GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE: B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE: APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions.
Neutral
Business Wire
1 week ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approxim.
Neutral
Business Wire
2 weeks ago
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting. Arrowh.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a kn.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company's Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and v.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. “Dysregulated activation of the complement sy.
Neutral
Business Wire
2 months ago
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead's leadership in the delivery of siRNA to multipl.
Neutral
Business Wire
2 months ago
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 4, 2024, 2:10 p.m. EST The APA/JPS/CAP/IAP 2024 Joint Meeting – De.
Neutral
Seeking Alpha
2 months ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardiometabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Jasmine Fels - UBS Luca Issi - RBC Capital Andrea Newkirk - Goldman Sachs Maury Raycroft - Jefferies Dina Ramadane - Bank of America Patrick Trucchio - H.C. Wainwright Edward Tenthoff - PSC Mayank Mamtani - B.
Neutral
Business Wire
2 months ago
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions.
Charts implemented using Lightweight Charts™